Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 175

1.

Ambulatory blood pressure monitoring and neurocognitive function in children with primary hypertension.

Kupferman JC, Batisky DL, Samuels J, Adams HR, Hooper SR, Wang H, Lande MB.

Pediatr Nephrol. 2018 Oct;33(10):1765-1771. doi: 10.1007/s00467-018-3954-y. Epub 2018 Jun 12.

PMID:
29948308
2.

Short-Term Administration of Mycophenolate Is Well-Tolerated in CLN3 Disease (Juvenile Neuronal Ceroid Lipofuscinosis).

Augustine EF, Beck CA, Adams HR, Defendorf S, Vierhile A, Timm D, Weimer JM, Mink JW, Marshall FJ.

JIMD Rep. 2018 Jun 20. doi: 10.1007/8904_2018_113. [Epub ahead of print]

3.

Developing and Implementing Performance Outcome Assessments: Evidentiary, Methodologic, and Operational Considerations.

Richardson E, Burnell J, Adams HR, Bohannon RW, Bush EN, Campbell M, Chen WH, Coons SJ, Papadopoulos E, Reeve BR, Rooks D, Daniel G.

Ther Innov Regul Sci. 2019 Jan;53(1):146-153. doi: 10.1177/2168479018772569. Epub 2018 May 8.

PMID:
29739255
4.

Neurocognitive Function in Children with Primary Hypertension after Initiation of Antihypertensive Therapy.

Lande MB, Batisky DL, Kupferman JC, Samuels J, Hooper SR, Falkner B, Waldstein SR, Szilagyi PG, Wang H, Staskiewicz J, Adams HR.

J Pediatr. 2018 Apr;195:85-94.e1. doi: 10.1016/j.jpeds.2017.12.013. Epub 2018 Feb 3.

PMID:
29398058
5.

Severe obstructive sleep apnea in children with elevated blood pressure.

Hinkle J, Connolly HV, Adams HR, Lande MB.

J Am Soc Hypertens. 2018 Mar;12(3):204-210. doi: 10.1016/j.jash.2017.12.010. Epub 2018 Jan 3.

PMID:
29373256
6.

Cognitive endpoints for therapy development for neuronopathic mucopolysaccharidoses: Results of a consensus procedure.

van der Lee JH, Morton J, Adams HR, Clarke L, Ebbink BJ, Escolar ML, Giugliani R, Harmatz P, Hogan M, Jones S, Kearney S, Muenzer J, Rust S, Semrud-Clikeman M, Wijburg FA, Yu ZF, Janzen D, Shapiro E.

Mol Genet Metab. 2017 Jun;121(2):70-79. doi: 10.1016/j.ymgme.2017.05.004. Epub 2017 May 6.

7.

Screening tools for tic disorders-Focus on development or implementation?

Augustine EF, Adams HR, Mink JW.

Mov Disord. 2017 Jun;32(6):946. doi: 10.1002/mds.26981. Epub 2017 Apr 24. No abstract available.

PMID:
28436544
8.

Management Strategies for CLN2 Disease.

Williams RE, Adams HR, Blohm M, Cohen-Pfeffer JL, de Los Reyes E, Denecke J, Drago K, Fairhurst C, Frazier M, Guelbert N, Kiss S, Kofler A, Lawson JA, Lehwald L, Leung MA, Mikhaylova S, Mink JW, Nickel M, Shediac R, Sims K, Specchio N, Topcu M, von Löbbecke I, West A, Zernikow B, Schulz A.

Pediatr Neurol. 2017 Apr;69:102-112. doi: 10.1016/j.pediatrneurol.2017.01.034. Epub 2017 Feb 4. Review.

9.

Design of a Multisite Study Assessing the Impact of Tic Disorders on Individuals, Families, and Communities.

Augustine EF, Adams HR, Bitsko RH, van Wijngaarden E, Claussen AH, Thatcher A, Hanks CE, Lewin AB, O'Connor TG, Vierhile A, Danielson ML, Kurlan R, Murphy TK, Mink JW.

Pediatr Neurol. 2017 Mar;68:49-58.e3. doi: 10.1016/j.pediatrneurol.2016.10.017. Epub 2016 Nov 8.

10.

Phenotype Differentiation of FOXG1 and MECP2 Disorders: A New Method for Characterization of Developmental Encephalopathies.

Ma M, Adams HR, Seltzer LE, Dobyns WB, Paciorkowski AR.

J Pediatr. 2016 Nov;178:233-240.e10. doi: 10.1016/j.jpeds.2016.08.032. Epub 2016 Sep 15.

11.

Neurocognitive Function in Children with Primary Hypertension.

Lande MB, Batisky DL, Kupferman JC, Samuels J, Hooper SR, Falkner B, Waldstein SR, Szilagyi PG, Wang H, Staskiewicz J, Adams HR.

J Pediatr. 2017 Jan;180:148-155.e1. doi: 10.1016/j.jpeds.2016.08.076. Epub 2016 Sep 29.

12.

Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions.

Shapiro E, Bernstein J, Adams HR, Barbier AJ, Buracchio T, Como P, Delaney KA, Eichler F, Goldsmith JC, Hogan M, Kovacs S, Mink JW, Odenkirchen J, Parisi MA, Skrinar A, Waisbren SE, Mulberg AE.

Mol Genet Metab. 2016 Jun;118(2):65-9. doi: 10.1016/j.ymgme.2016.04.006. Epub 2016 Apr 14.

13.

Neurodevelopmental outcomes after neonatal cardiac surgery: Role of cortical isoelectric activity.

Seltzer L, Swartz MF, Kwon J, Burchfiel J, Cholette JM, Wang H, Sweeney D, Adams HR, Meagher C, Angona R, Guillet R, Alfieris GM.

J Thorac Cardiovasc Surg. 2016 Apr;151(4):1137-42. doi: 10.1016/j.jtcvs.2015.10.065. Epub 2015 Oct 27.

14.

Parent-reported multi-national study of the impact of congenital and childhood onset myotonic dystrophy.

Johnson NE, Ekstrom AB, Campbell C, Hung M, Adams HR, Chen W, Luebbe E, Hilbert J, Moxley RT 3rd, Heatwole CR.

Dev Med Child Neurol. 2016 Jul;58(7):698-705. doi: 10.1111/dmcn.12948. Epub 2015 Oct 28.

15.

Neurocognitive Changes after Sustained Ketamine Administration in Children with Chronic Pain.

Bredlau AL, Harel BT, McDermott MP, Dworkin RH, Korones DN, Dolan JG, Adams HR.

J Palliat Care Med. 2015 Mar;5(2). pii: 215. Epub 2015 Mar 27.

16.

Remote Assessment of Cognitive Function in Juvenile Neuronal Ceroid Lipofuscinosis (Batten disease): A Pilot Study of Feasibility and Reliability.

Ragbeer SN, Augustine EF, Mink JW, Thatcher AR, Vierhile AE, Adams HR.

J Child Neurol. 2016 Mar;31(4):481-7. doi: 10.1177/0883073815600863. Epub 2015 Sep 2.

17.

SUICIDAL THOUGHTS AND BEHAVIORS IN CHILDREN AND ADOLESCENTS WITH CHRONIC TIC DISORDERS.

Storch EA, Hanks CE, Mink JW, McGuire JF, Adams HR, Augustine EF, Vierhile A, Thatcher A, Bitsko R, Lewin AB, Murphy TK.

Depress Anxiety. 2015 Oct;32(10):744-53. doi: 10.1002/da.22357. Epub 2015 Feb 24.

18.

Standardized assessment of seizures in patients with juvenile neuronal ceroid lipofuscinosis.

Augustine EF, Adams HR, Beck CA, Vierhile A, Kwon J, Rothberg PG, Marshall F, Block R, Dolan J, Mink JW; Batten Study Group.

Dev Med Child Neurol. 2015 Apr;57(4):366-71. doi: 10.1111/dmcn.12634. Epub 2014 Nov 11.

19.

Sleep disordered breathing as measured by SRBD-PSQ and neurocognition in children with hypertension.

Lande MB, Hooper SR, Batisky DL, Kupferman JC, Szilagyi PG, Samuels JA, Adams HR.

Am J Hypertens. 2015 Apr;28(4):552-8. doi: 10.1093/ajh/hpu180. Epub 2014 Sep 20.

20.

Utility of the diagnostic interview schedule for children for assessing Tourette syndrome in children.

Lewin AB, Mink JW, Bitsko RH, Holbrook JR, Parker-Athill EC, Hanks C, Storch EA, Augustine EF, Adams HR, Vierhile AE, Thatcher AR, Murphy TK.

J Child Adolesc Psychopharmacol. 2014 Jun;24(5):275-84. doi: 10.1089/cap.2013.0128. Epub 2014 May 9.

21.

Blood pressure and school performance.

Lande MB, Kupferman JC, Hooper SR, Pavlakis SG, Batisky DL, Adams HR.

Psychosom Med. 2014 Feb;76(2):163-6. doi: 10.1097/PSY.0000000000000033. Epub 2014 Jan 26. No abstract available.

22.

Experience, knowledge, and opinions about childhood genetic testing in Batten disease.

Adams HR, Rose K, Augustine EF, Kwon JM, deBlieck EA, Marshall FJ, Vierhile A, Mink JW, Nance MA.

Mol Genet Metab. 2014 Feb;111(2):197-202. doi: 10.1016/j.ymgme.2013.10.017. Epub 2013 Nov 4.

23.

Clinical trials in rare disease: challenges and opportunities.

Augustine EF, Adams HR, Mink JW.

J Child Neurol. 2013 Sep;28(9):1142-50. doi: 10.1177/0883073813495959.

24.

Neurobehavioral features and natural history of juvenile neuronal ceroid lipofuscinosis (Batten disease).

Adams HR, Mink JW; University of Rochester Batten Center Study Group.

J Child Neurol. 2013 Sep;28(9):1128-36. doi: 10.1177/0883073813494813. Review.

25.

Classification and natural history of the neuronal ceroid lipofuscinoses.

Mink JW, Augustine EF, Adams HR, Marshall FJ, Kwon JM.

J Child Neurol. 2013 Sep;28(9):1101-5. doi: 10.1177/0883073813494268. Epub 2013 Jul 9. Review.

26.

A multicenter study of neurocognition in children with hypertension: methods, challenges, and solutions.

Lande MB, Adams HR, Kupferman JC, Hooper SR, Szilagyi PG, Batisky DL.

J Am Soc Hypertens. 2013 Sep-Oct;7(5):353-62. doi: 10.1016/j.jash.2013.05.003. Epub 2013 Jun 20.

27.

Oral ketamine for children with chronic pain: a pilot phase 1 study.

Bredlau AL, McDermott MP, Adams HR, Dworkin RH, Venuto C, Fisher SG, Dolan JG, Korones DN.

J Pediatr. 2013 Jul;163(1):194-200.e1. doi: 10.1016/j.jpeds.2012.12.077. Epub 2013 Feb 10.

28.

Primary hypertension and neurocognitive and executive functioning in school-age children.

Kupferman JC, Lande MB, Adams HR, Pavlakis SG.

Pediatr Nephrol. 2013 Mar;28(3):401-8. doi: 10.1007/s00467-012-2215-8. Epub 2012 Jun 13. Review.

29.

Neurocognitive alterations in hypertensive children and adolescents.

Lande MB, Kupferman JC, Adams HR.

J Clin Hypertens (Greenwich). 2012 Jun;14(6):353-9. doi: 10.1111/j.1751-7176.2012.00661.x. Epub 2012 May 21. Review.

30.

Big brain/smart brain.

Rosenberger PB, Adams HR.

Neurology. 2011 Oct 18;77(16):1504-5. doi: 10.1212/WNL.0b013e318233b3d4. Epub 2011 Oct 12. No abstract available.

PMID:
21998321
31.

Learning and attention problems among children with pediatric primary hypertension.

Adams HR, Szilagyi PG, Gebhardt L, Lande MB.

Pediatrics. 2010 Dec;126(6):e1425-9. doi: 10.1542/peds.2010-1899. Epub 2010 Nov 8.

32.

Genotype does not predict severity of behavioural phenotype in juvenile neuronal ceroid lipofuscinosis (Batten disease).

Adams HR, Beck CA, Levy E, Jordan R, Kwon JM, Marshall FJ, Vierhile A, Augustine EF, de Blieck EA, Pearce DA, Mink JW.

Dev Med Child Neurol. 2010 Jul;52(7):637-43. doi: 10.1111/j.1469-8749.2010.03628.x. Epub 2010 Feb 19. Erratum in: Dev Med Child Neurol. 2010 Oct;52(10):890.

33.

Increased T-regulatory cells within lymphocyte follicles in moderate COPD.

Plumb J, Smyth LJ, Adams HR, Vestbo J, Bentley A, Singh SD.

Eur Respir J. 2009 Jul;34(1):89-94. doi: 10.1183/09031936.00100708. Epub 2009 Feb 5.

34.

Neuropsychological symptoms of juvenile-onset batten disease: experiences from 2 studies.

Adams HR, Kwon J, Marshall FJ, de Blieck EA, Pearce DA, Mink JW.

J Child Neurol. 2007 May;22(5):621-7.

35.

Blood pressure as an independent prognostic factor in acute ischemic stroke.

Jensen MB, Yoo B, Clarke WR, Davis PH, Adams HR Jr.

Can J Neurol Sci. 2006 Feb;33(1):34-8.

PMID:
16583719
36.
37.

PET evaluation of [(18)F]FCWAY, an analog of the 5-HT(1A) receptor antagonist, WAY-100635.

Carson RE, Lang L, Watabe H, Der MG, Adams HR, Jagoda E, Herscovitch P, Eckelman WC.

Nucl Med Biol. 2000 Jul;27(5):493-7.

PMID:
10962257
38.

Kinetic analysis of the 5-HT2A ligand [11C]MDL 100,907.

Watabe H, Channing MA, Der MG, Adams HR, Jagoda E, Herscovitch P, Eckelman WC, Carson RE.

J Cereb Blood Flow Metab. 2000 Jun;20(6):899-909.

PMID:
10894173
39.

Evolution in veterinary practice despite revolving concerns.

Adams HR.

J Am Vet Med Assoc. 2000 Nov 15;217(10):1460-1. No abstract available.

PMID:
11128532
40.

Enhanced prostanoid-mediated vasorelaxation in pulmonary arteries isolated during experimental endotoxemia.

Myers TP, Myers PR, Adams HR, Parker JL.

Shock. 1999 Jun;11(6):436-42.

PMID:
10454834
41.

Development of fluorine-18-labeled 5-HT1A antagonists.

Lang L, Jagoda E, Schmall B, Vuong BK, Adams HR, Nelson DL, Carson RE, Eckelman WC.

J Med Chem. 1999 May 6;42(9):1576-86.

PMID:
10229627
42.

Contractile function and myoplasmic free Ca2+ (Cam) in coronary and mesenteric arteries of endotoxemic guinea pigs.

Jones JJ, Rapps JA, Sturek M, Mattox ML, Adams HR, Parker JL.

Shock. 1999 Jan;11(1):64-71.

PMID:
9921719
43.

Endotoxemia-induced myocardial dysfunction is not associated with changes in myofilament Ca2+ responsiveness.

Rigby SL, Hofmann PA, Zhong J, Adams HR, Rubin LJ.

Am J Physiol. 1998 Feb;274(2 Pt 2):H580-90.

PMID:
9486262
44.

Reduced L-type calcium current in ventricular myocytes from endotoxemic guinea pigs.

Zhong J, Hwang TC, Adams HR, Rubin LJ.

Am J Physiol. 1997 Nov;273(5 Pt 2):H2312-24.

PMID:
9374768
46.

Following up endogenous nitric oxide article.

Adams HR.

J Am Vet Med Assoc. 1997 Apr 1;210(7):888. No abstract available.

PMID:
9096709
47.

Chronic endotoxemia and endothelium-dependent vasodilation in coronary arteries.

Myers PR, Gupta M, Rogers S, Mattox ML, Adams HR, Parker JL.

Shock. 1996 Oct;6(4):267-73.

PMID:
8902944
48.

Physiologic, pathophysiologic, and therapeutic implications for endogenous nitric oxide.

Adams HR.

J Am Vet Med Assoc. 1996 Oct 1;209(7):1297-302. Review. No abstract available.

PMID:
8837656
49.

Evidence for endothelium-derived relaxing factor/nitric oxide in equine digital arteries.

Cogswell AM, Johnson PJ, Adams HR.

Am J Vet Res. 1995 Dec;56(12):1637-41.

PMID:
8599526
50.

Endotoxin-induced myocardial dysfunction: is there a role for nitric oxide?

Keller RS, Jones JJ, Kim KF, Myers PR, Adams HR, Parker JL, Rubin LJ.

Shock. 1995 Nov;4(5):338-44.

PMID:
8595520

Supplemental Content

Loading ...
Support Center